'Podnosis': A deep dive into the OTC approval of Narcan, the opioid overdose drug

Preview

来源: FierceHealthcare

None

This week, we'll introduce you to our sister podcast, "The Top Line."

On March 29, the FDA approved the Narcan nasal spray for over-the-counter sales. It is the first naloxone product approved for use without a prescription. In this episode of "The Top Line," Fierce Pharma staff writer Fraiser Kansteiner continues our miniseries to explore what that means for the opioid epidemic. The series will tackle questions about using the product, its accessibility and whether the move will save lives.

To learn more about the topics in this episode:

Emergent makes history with first FDA nod for over-the-counter naloxone

Teva, Sandoz have launched Narcan generics, but Emergent's branded option should still thrive: analysts

Adapt tests ads urging opioid users' loved ones to stock Narcan at home

Eyeing $1B in annual sales, Emergent BioSolutions to buy Narcan maker Adapt for $735M

Ahead of next month's FDA decision, Emergent aces AdComm for over-the-counter Narcan nod

Virtual Roundtable: Remote Therapeutic Monitoring, The Future of Virtual Care Management

"The Top Line" and "Podnosis" are produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。